ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Switching from deuruxolitinib to baricit…

Switching from deuruxolitinib to baricitinib in alopecia areata: a real-world cohort of 36 patients.

Journal of the American Academy of Dermatology·August 6
DermatologyLimited evidenceAlopecia AreataRetrospective Cohort StudyJAK InhibitorAdultLitfuloOlumiantBaricitinibDeuruxolitinib

Summary

View source

What was studied

This real-world cohort study evaluated outcomes in 36 patients with alopecia areata who switched from deuruxolitinib to baricitinib, examining the reasons for switching and hair regrowth responses after transition.

Key findings

Specific response rates and absolute outcome numbers are not available from the provided abstract, but the study reports real-world hair regrowth outcomes in 36 patients following the JAK inhibitor switch.

Study limitations

Small cohort of only 36 patients limits generalizability; real-world design without a control arm; potential for confounding by indication given switching was likely driven by clinical or access factors.

Clinical implications

For patients with alopecia areata who cannot continue deuruxolitinib, switching to baricitinib may be a viable option; this real-world data can help guide shared decision-making when JAK inhibitor transitions are needed.

Related Questions

Explore related topics

What are the outcomes of switching between JAK inhibitors in alopecia areata?How does baricitinib compare to deuruxolitinib for alopecia areata treatment?What are the reasons for JAK inhibitor discontinuation or switching in alopecia areata?

Publication Details

Year
2026
Journal
Journal of the American Academy of Dermatology
Sample Size
n=36
Source
View article
Keep scrolling
More content below.
Up Next